84-1515-91 ［取扱停止］PABPN1, CT (PABPN1, PAB2, PABP2, Polyadenylate-binding protein 2, Nuclear poly(A)-binding protein 1, Poly(A)-binding protein II, Polyadenylate-binding nuclear protein 1) (AP) 200ul 039602-AP
84-1515-91 ［取扱停止］PABPN1, CT (PABPN1, PAB2, PABP2, Polyadenylate-binding protein 2, Nuclear poly(A)-binding protein 1, Poly(A)-binding protein II, Polyadenylate-binding nuclear protein 1) (AP) 200ul 039602-AP
This gene encodes an abundant nuclear protein that binds with high affinity to nascent poly(A) tails.
The protein is required for progressive and efficient polymerization of poly(A) tails on the 3' ends of eukaryotic genes and controls the size of the poly(A) tail to about 250 nt.
At steady-state, this protein is localized in the nucleus whereas a different poly(A) binding protein is localized in the cytoplasm.
An expansion of the trinucleotide (GCG) repeat from normal 6 to 8-13 at the 5' end of the coding region of this gene leads to autosomal dominant oculopharyngeal muscular dystrophy (OPMD) disease.
Multiple splice variants have been described but their full-length nature is not known.
One splice variant includes introns 1 and 6 but no protein is formed.
Applications:Suitable for use in Western Blot, ELISA
DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid.
Dilute required amount only prior to immediate use.
Further dilutions can be made in assay buffer.
For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Note: Applications are based on unconjugated antibody.
仕様
Size：200ul
Host：rabbit
Source Antibody：human
Grade：Affinity Purified
Purity：Purified by Protein A affinity chromatography.
Form：Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with Alkaline Phophatase (AP).
Specificity：Human
Isotype：IgG
Calc Applications Abbrev：E WB
Calc Crossreactivity：Hu
Immunogen：PABPN1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 269-298 amino acids from the C-terminal region of human PABPN1.
